TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial



Palmer, Daniel H ORCID: 0000-0002-7147-5703, Valle, Juan W, Ting Ma, Yuk, Faluyi, Olusola, Neoptolemos, John P, Jensen Gjertsen, Trine, Iversen, Berit, Amund Eriksen, Jon, Moller, Anne-Sophie, Aksnes, Anne-Kirsti
et al (show 2 more authors) (2020) TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. BRITISH JOURNAL OF CANCER, 122 (7). 971 - 977.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 16 Jul 2021 08:17
Last Modified: 07 Oct 2021 11:48
DOI: 10.1038/s41416-020-0752-7
Open Access URL: https://doi.org/10.1038/s41416-020-0752-7
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3130240